SCHEMBL7141053

SCHEMBL7141053

CNCC(=O)N(C)c1ccc(CO)cc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
PPIB P23284 2/20 0.43
HDAC1 Q13547 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
MMP8 P22894 1/20 0.37
DRD4 P21917 1/20 0.37
MGLL Q99685 1/20 0.37
THRB P10828 1/20 0.36
ALDH1A1 P00352 1/20 0.35
CYP3A4 P08684 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
KMT2A Q03164 2/20 0.34
MLYCD O95822 2/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8353503 0.82 THRB (0.49) PPIBTHRBALDH1A1TSHRKMT2A
SCHEMBL7137957 0.82 PPIB (0.45) PPIBHDAC1HDAC6THRBALDH1A1
SCHEMBL7141047 0.82 PPIB (0.40) CA1CA2PPIBHDAC1HDAC6
SCHEMBL7508139 0.81 DRD4 (0.47) DRD4ALDH1A1CYP3A4TSHRTDP1
SCHEMBL24233024 0.81 POLQ (0.46) ALDH1A1
SCHEMBL1821412 0.80 PPIB (0.52) PPIBDRD4ALDH1A1CYP3A4KMT2A
SCHEMBL20739091 0.80 KMT2A (0.37) CA1CA2PPIBHDAC1HDAC6
SCHEMBL7141049 0.79 CA1 (0.40) CA1CA2PPIBHDAC1HDAC6
SCHEMBL7587051 0.79 ROCK2 (0.49) CA1CA2HDAC1HDAC6MMP8
SCHEMBL7148527 0.79 PPIB (0.40) PPIBHDAC1HDAC6DRD4THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US claimed
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP CA1 551/4885CA2 425/4885PPIB 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.